Navigation Links
UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
Date:11/5/2013

SYDNEY, Nov. 5, 2013 /PRNewswire/ -- UbiVac, a clinical stage cancer immunotherapy company based in Portland, OR, announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of its first-in-class autophagosome DRibble vaccine, DPV-001, in two presentations at the 15th World Conference for Lung Cancer, in Sydney, from October 27-30. The multicenter, randomized Phase II clinical trial of DPV-001 is supported by a US$3.4 million National Cancer Institute (NCI) grant and will involve 48 individuals with definitively treated stage IIIA/B non-small cell lung cancer (NSCLC). A description of DPV-001, an "off-the-shelf vaccine," was presented by Dr. Helen Ross, Mayo Clinic Arizona, in an oral session (abstract #O-08.01). This next generation vaccine contains a system for targeting to dendritic cells, at least 9 cancer antigens prioritized by an NCI advisory panel and 5 toll-like receptor agonists to boost immunity. "Patients with locally advanced lung cancer still have a very high risk of cancer returning despite our most aggressive treatments," said Dr. Rachel Sanborn, the trial's principal investigator and the Co-Director of Thoracic Oncology, Providence Cancer Center, Portland, Oregon. "This novel vaccine approach may help the immune system recognize and fight remaining cancer cells." In a presentation of the Phase 1 trial in patients with Stage IV NSCLC, the authors reported that immune responses were detected in a majority of the evaluable patients (abstract # P-3.11-032).

"UbiVac is excited to pioneer this first-in-class vaccine technology to patients with NSCLC," said Dr. Hong-Ming Hu, inventor of autophagosome DRibble technology, Co-founder and CSO of UbiVac. "In addition to lung cancer, UbiVac is actively pursuing the application of this technology, with our partners and collaborators, for the treatment of head and neck, hepatocellular, prostate, colon and breast cancer."

UbiVac, spun-out from the Providence Health System in 2005, recently was judged by Oregon CEOs as the top "Presenting Company" at the Oregon Bioscience Association annual meeting has three vaccine platform technologies under development: DRibbles, a nanotechnology platform and a disabled cytomegalovirus (CMV) vector platform.

The ongoing activities reported in this release are supported by the NCI of the National Institutes of Health under Award Numbers R44CA121612 and U43CA165048. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the National Institutes of Health.


'/>"/>
SOURCE UbiVac
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biotest Opens New Plasma Center in Melbourne, Florida
2. Industry Landscape Opens Doors for GeoBargain Polydex Pharmaceuticals
3. AdvaMed 2013: The MedTech Conference Opens Monday in Washington, D.C.
4. Unique Glaucoma Test Through Eyelid DIATON Opens Doctors Eyes to Possibility of In-Office Glaucoma Test at Pri-Med East and American Academy of Family Physicians, AAFP
5. Dr. George O. Gavrila Opens Baltimore Tattoo Removal, Offers Astanza Duality Laser Technology
6. Boston Scientific Opens Institute For Advancing Science, Innovation Center In Shanghai
7. BioReliance Opens New U.S. Clearance Services Laboratories; Completes Global Facility Upgrade Plan
8. MinuteClinic Opens Its First Walk-in Medical Clinic in Southwest Virginia
9. Orange County Physician Owned Medical Group Opens Pioneering Medical Facility
10. Life Technologies Opens State-of-the-Art DNA Forensics Laboratory in India
11. MinuteClinic Opens Its First Medical Clinics in Lehigh Valley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, ... Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to a ... changes during this period order for their new policy to go into effect in ...
(Date:12/2/2016)... ... 2016 , ... More than half of American teens report losing their virginity ... with their child about sex related topics, less than 60 percent spoke about deeper ... announce the launch of its second edition of the “Sexual Wellness” campaign, aiming to ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... ... December 02, 2016 , ... On November 24th, ... families from eight different sites throughout Miami-Dade and Broward counties. This is the ... very hard on Thanksgiving morning by putting together individual meals via assembly lines ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
Breaking Medicine News(10 mins):